Breast AbscessMANAGEMENT

GENITOURINARY AND REPRODUCTIVE PRESENTATIONS · 12 SECTIONS

⚲

664 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Acute Kidney Injury (ATN)Acute Kidney Injury (Post-renal)Acute Kidney Injury (Pre-renal)Amniotic Fluid Embolism Balanitis Bladder Rupture Breast Abscess Cystitis Dialysis access complications Ectopic pregnancy Epididymitis Glomerulonephritis Hematuria (gross)Hydrocele Interstitial Cystitis Mastitis Mittelschmerz Nephrolithiasis Nephrotic Syndrome Flare Nutcracker Syndrome Orchitis Ovarian Cyst Rupture Ovarian hyperstimulation syndrome Ovarian torsion Paraphimosis Pelvic Congestion Syndrome Pelvic Inflammatory Disease (PID)Peritoneal dialysis peritonitis Phimosis Priapism Prostatitis Pyelonephritis Renal laceration Renal transplant complications and rejection Ruptured ovarian cyst Testicular torsion Torsion of Appendix Testis Tubo-ovarian abscess Ureteral Rupture Urethritis Urinary Retention Urinary tract infection (uncomplicated)Urolithiasis (renal colic)Vaginal bleeding (non-pregnant)Vaginitis (Bacterial)Vaginitis (Candidal)Varicocele Vulvovaginal Hematoma

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp44

Immediate priorities

›Time-critical red flags requiring urgent action

›Sepsis or SIRS criteria met

›Temperature >38°C or <36°C

›Heart rate >90 beats/min

›Respiratory rate >24 breaths/min

›WBC >12.0 x10^9/L or <4.0 x10^9/L

›Hypotension or hemodynamic instability

›SBP <90 mmHg

›MAP <65 mmHg

›Signs of necrotizing soft tissue infection

›Crepitus on palpation

›Rapidly advancing skin necrosis or dusky discoloration

›Pain disproportionate to exam findings

›Rapidly expanding erythema involving ≥1/3 of breast

›Cannot-miss: inflammatory breast cancer (IBC)

›Peau d'orange, skin thickening, or skin dimpling

Stabilization actions

›Sepsis resuscitation bundle if SIRS criteria met

›IV access with two large-bore peripheral IVs

›Send blood cultures before antibiotics

›IV broad-spectrum antibiotics within 1 hour

›IV crystalloid 30 ml/kg bolus for hypotension

›Reassess hemodynamics after each 500 ml aliquot

›Vasopressor initiation if MAP <65 mmHg after adequate fluid resuscitation

›Lactate measurement

›Lactate ≥2 mmol/l indicates organ hypoperfusion

›Repeat lactate in 2–4 hours if initially elevated

02History/hx66

Presentation pattern

›Core breast symptoms

›Breast pain

›Onset, duration, and progression

›Acuity relative to prior mastitis episode

›Breast swelling and erythema

›Extent and progression

›Skin changes: peau d'orange, dimpling, ulceration

›Palpable mass or fluctuance

›Onset timing

›Rate of enlargement

Lactation history

›Lactation status

›Currently breastfeeding

›Duration of lactation

›Postpartum timing

›Latch difficulties or nipple trauma

›Cracked or damaged nipples

›Missed feedings or milk stasis

›Pumping history

›Frequency and adequacy

›Non-professional breast massage (risk factor for abscess progression)

Systemic symptoms

›Constitutional symptoms

›Fever and chills

›Rigors

›Antipyretic use masking fever

›Malaise and fatigue

03Physical Exam/exam46

Vital signs

›Hemodynamic and systemic assessment

›Temperature

›Fever >38°C: systemic infection

›Hypothermia: severe sepsis marker

›Heart rate

›Tachycardia >90: SIRS criterion

›Persistent tachycardia after drainage: concern for ongoing sepsis

›Blood pressure

›SBP <90 mmHg or MAP <65 mmHg: shock physiology

›Respiratory rate

›>24 breaths/min: SIRS criterion

Breast exam

›Inspection and palpation findings

›Erythema extent

›Demarcate borders with skin marker for monitoring

›Involvement ≥1/3 of breast: IBC red flag

›Induration and warmth

›Firm, mass-like area without fluctuance: phlegmon pattern (do not drain)

›Fluctuance: confirms drainable collection

›Skin changes

›Peau d'orange: lymphatic obstruction

›Skin dimpling or nipple retraction: malignancy concern

›Skin ulceration or breakdown: advanced infection

›Nipple exam

›Nipple retraction or inversion

›Nipple discharge: character and quantity

›Nipple excoriation: Paget disease concern

04Differential Diagnosis/ddx50

Life-threatening and cannot-miss diagnoses

›Inflammatory breast cancer (IBC)

›ICD-10 C50.9 (breast cancer NOS)

›Erythema involving ≥1/3 of breast

›Peau d'orange, skin thickening

›Absent fever in early IBC

›Non-lactating patient without infectious trigger

›Failure to respond to antibiotics within 7–10 days: biopsy required

›Necrotizing soft tissue infection

›ICD-10 M72.6

›Crepitus, rapidly advancing necrosis

›Pain disproportionate to exam

›Surgical emergency

Infectious mimics

›Phlegmon

›ICD-10 L03.119

›Firm, ill-defined induration without drainable collection

›Ultrasound: no discrete fluid pocket

›Treatment: antibiotics ≥10 days, no drainage

›Cellulitis without abscess

›ICD-10 L03.119

›Diffuse erythema and warmth without fluctuance

›No discrete collection on ultrasound

›Differentiating feature: antibiotics alone sufficient

›Periductal mastitis (PDM-SMOLD)

›ICD-10 N61.0

›Recurrent subareolar abscesses

›Strong association with smoking

05Laboratory Tests/lt41

Microbiology

›Abscess fluid culture and sensitivity

›Send with every drainage procedure

›Guides antibiotic adjustment

›Identifies MRSA or resistant organisms

›Request anaerobic culture for non-lactational abscesses

›Anaerobes common in periductal disease

›Bacteroides and Peptostreptococcus species

›Blood cultures

›Indicated when SIRS criteria met or bacteremia suspected

›Collect two sets before antibiotics

›Low yield in uncomplicated abscess

›Milk culture

›Indicated in high-risk patients

›MRSA contact or healthcare exposure

›Failed antibiotics course

›Immunocompromised patient

›Infant in NICU

Infection and inflammatory markers

›Complete blood count

›Leukocytosis: supports systemic infection

›WBC >12.0 x10^9/L: SIRS criterion

›Leukopenia: severe sepsis or immunosuppression marker

›Limited diagnostic value alone (elevated in both infectious and inflammatory conditions)

›C-reactive protein

›Elevated in both abscess and IBC

›Non-specific; adjunct only

›Trend useful if disposition is uncertain

06Diagnostic Tests/dt75

Scoring Systems

›No validated scoring system specific to breast abscess

›SIRS criteria used for sepsis risk stratification

›Two or more SIRS criteria indicate systemic infection

›Temperature >38°C or <36°C

›Heart rate >90 beats/min

›Respiratory rate >24 breaths/min

›WBC >12 x10^9/L or <4 x10^9/L

›LRINEC score (Laboratory Risk Indicator for Necrotizing Fasciitis)

›Score ≥6: moderate risk for necrotizing infection

›Score ≥8: high risk; surgical exploration indicated

›Parameters: CRP, WBC, sodium, glucose, creatinine, hemoglobin

Scoring Systems — Abscess Size Classification

›Size-based management classification

›Small abscess <3 cm

›First-line: needle aspiration ± ultrasound guidance

›Single or serial aspirations

›Moderate abscess 3–5 cm

›Lactational: stab incision with gravity drain placement

›Non-lactational: aspiration attempt reasonable first-line

›Large abscess >5 cm or multiloculated

›Stab incision with drain or operative drainage

›Drainage under sedation if not tolerated in office

MRI

›MRI breast indications in abscess

›Not first-line for acute breast abscess management

›Reserved for complex or recurrent cases

›Used when ultrasound is inconclusive and malignancy concern persists

›IBC or malignancy evaluation

›Multifocal disease assessment

›Skin thickening quantification

›Axillary lymphadenopathy characterization

›Granulomatous mastitis workup

›Enhancement pattern: rim-enhancing masses

›Extent of disease mapping before surgical planning

›MRI limitations in acute infection

›Availability and cost

›Motion artifact from pain and discomfort

›Gadolinium not recommended in pregnancy or renal impairment

›CT chest/thorax indications

›Not routinely indicated for breast abscess

›Use reserved for systemic sepsis workup

›Evaluation of deep chest wall or pectoral space extension

›CT of chest and axilla for complex cases

›Retromammary or deep space infection

›Pectoral or intercostal muscle involvement

›Pneumothorax or pleural effusion assessment

›CT limitations

›Radiation exposure

›Inferior soft tissue resolution vs MRI for breast parenchyma

›Gadolinium or contrast allergy considerations

Ultrasound

›Breast ultrasound: first-line imaging for breast abscess

›Confirms drainable fluid collection

›Sensitivity and specificity high for fluid detection

›Distinguishes abscess from phlegmon (ill-defined, no discrete pocket)

›Characterizes collection

›Size measurement (guides drainage approach)

›Loculation assessment: simple vs multiloculated

›Depth from skin surface

›Guides drainage procedure

›Real-time needle aspiration guidance

›Optimal aspiration site identification

›Post-drainage residual cavity assessment

›ACEP ultrasound guidelines

›Point-of-care ultrasound for soft tissue abscess: ACEP 2023 guidelines support use

›Identifies occult collections not apparent on exam

›Reduces failed drainage attempts

›Reduces unnecessary drainage of phlegmon

›Doppler ultrasound adjunct

›Vascularity assessment

›Increased perilesional vascularity: inflammatory/infectious

›Internal vascularity: raises concern for solid lesion or malignancy

›Follow-up ultrasound indications

›Symptoms not improving after drainage

›Residual or recurrent collection assessment

›Repeat aspiration guidance if needed

›IBC follow-up after antibiotic trial

›Ultrasound-guided core biopsy of thickened skin if no improvement

07Disposition/dispo44

Discharge criteria

›Outpatient management criteria (majority of patients qualify)

›Hemodynamically stable and non-toxic appearing

›No SIRS criteria

›Tolerating oral intake

›Successful drainage performed in ED or clinic

›Fluid obtained for culture

›Drain placed if appropriate

›Oral antibiotics tolerated and prescribed

›Reliable medication adherence anticipated

›Reliable follow-up available

›48–72 hour wound check arranged

›Lactation consultant involvement for lactating patients

Admission criteria

›Indications for inpatient admission

›Sepsis or SIRS with hemodynamic instability

›Failed fluid resuscitation

›IV antibiotics required

›Failed outpatient management

›Failure to improve after 48 hours of appropriate antibiotics

›Recurrent collection after adequate drainage

›Immunocompromised patient with severe infection

›HIV, transplant, chronic steroids

›Elevated risk for rapid progression and bacteremia

›Inability to tolerate oral medications

›Nausea, vomiting, or swallowing difficulty

›Operative drainage required under sedation

›Large or complex abscess not manageable in office setting

08Treatment/t88

Source control — drainage

›Ultrasound-guided needle aspiration (first-line for <3 cm abscesses)

›Procedural technique

›Ultrasound guidance mandatory for accurate localization

›Local anesthetic: lidocaine 1% subcutaneous infiltration

›18-gauge needle aspiration; aspirate to dryness

›Outcomes

›Aspiration yields equivalent cure rate to I&D with better cosmesis

›Single aspiration may be sufficient for small collections

›Repeat aspiration acceptable if residual collection on follow-up ultrasound

›Safe to continue breastfeeding from affected breast even after lidocaine injection

›Stab incision with gravity drain (first-line for lactational abscess 3–5 cm)

›Procedural technique

›Incision as small as possible

›Incision as far from nipple-areolar complex as possible

›Break up loculations with finger or hemostat

›Place gravity (Penrose or similar) drain

›Drain management

›Remove drain in 3–5 days

›No wound packing: current guidelines recommend against packing

›Send abscess fluid for culture and sensitivity

›IDSA 2014 and ASBrS 2025 guidelines

›Operative drainage (for abscess >5 cm, multiloculated, or failed office procedure)

›Indications

›Office procedure not tolerated

›Failed aspiration

›Multiloculated collection requiring full breakdown

›General or IV sedation anesthesia required

›Coordinate with surgical team

›Intraoperative ultrasound may assist localization

Antibiotic therapy — lactational abscess

›First-line oral antibiotics

›Dicloxacillin 500 mg orally four times daily

›Duration: 10–14 days

›Safe during breastfeeding

›ASBrS 2025 and Cochrane 2015 first-line recommendation

›Cephalexin 500 mg orally four times daily (alternative first-line)

›Duration: 10–14 days

›Safe during breastfeeding

›Use if dicloxacillin unavailable

›Phlegmon present: extend antibiotics to at least 10 days before reassessing

›Penicillin allergy alternatives

›Cephalexin if non-anaphylactic penicillin allergy

›Cross-reactivity <2%

›Clindamycin 300 mg orally three times daily if anaphylactic penicillin allergy

›Duration 10–14 days

›Note high MRSA clindamycin resistance (up to 80% in some isolates)

Antibiotic therapy — non-lactational abscess

›First-line oral antibiotic

›Amoxicillin-clavulanate 875/125 mg orally twice daily

›Duration: 10–14 days

›Covers anaerobes common in periductal infections

›IDSA 2014 guideline recommendation

›Penicillin allergy alternative

›Erythromycin 500 mg orally four times daily PLUS metronidazole 500 mg orally three times daily

›Duration: 10–14 days

›Metronidazole provides anaerobic coverage

Antibiotic therapy — MRSA coverage

›Outpatient MRSA oral antibiotics

›Trimethoprim-sulfamethoxazole DS (160/800 mg) orally twice daily

›Duration: 10–14 days

›Safe in lactating women unless infant is premature or hyperbilirubinemic

›Doxycycline 100 mg orally twice daily

›Duration: 10–14 days

›Avoid in pregnancy and breastfeeding (theoretical risk of dental staining)

›Inpatient MRSA IV antibiotics

›Vancomycin IV 15–20 mg/kg every 8–12 hours (weight-based, renal dose adjustment)

›Target AUC/MIC 400–600 mg·h/L (Bayesian-guided dosing preferred)

›Monitor renal function every 48–72 hours

›Duration: until clinically improved and tolerating oral step-down

›Antibiotics to avoid

›Empiric quinolones: poor MRSA coverage and high resistance rates

›Macrolides alone: high MRSA resistance

Supportive treatment

›Analgesia

›Ibuprofen 400–600 mg orally every 6–8 hours

›Anti-inflammatory and analgesic benefit

›Safe in lactating women; use lowest effective dose

›Acetaminophen 650–1000 mg orally every 6 hours as adjunct

›Preferred in patients with NSAID contraindication

›Lactation management

›Continue breastfeeding from both breasts

›Breastfeeding is safe and encouraged even with abscess or after drainage

›Avoid aggressive breast massage or excessive pumping

›Aggressive massage is a risk factor for abscess progression

›ASBrS 2025 guideline: aggressive massage contraindicated

›Lactation consultant involvement

›Correct latch technique

›Optimal feeding schedule to prevent stasis

›Smoking cessation

›Counsel all patients with periductal mastitis or non-lactational abscess

›Smoking is the strongest modifiable risk factor for PDM-SMOLD

›Cessation reduces recurrence risk

09Special Populations/sp73

Pregnancy

›Pregnancy-specific considerations

›Breast abscess incidence increases in pregnancy due to breast engorgement and hormonal changes

›Lactational abscess may occur postpartum

›Non-lactational abscess may also occur in pregnancy

›Imaging safety

›Ultrasound: safe in pregnancy, preferred first-line imaging

›MRI without gadolinium: acceptable in second and third trimester if needed

›Gadolinium contrast: avoid in pregnancy

›Mammography: generally deferred unless malignancy strongly suspected; shielding required

›Antibiotic safety in pregnancy

›Cephalexin 500 mg orally four times daily

›Pregnancy category B; safe in all trimesters

›Amoxicillin-clavulanate 875/125 mg orally twice daily

›Pregnancy category B; safe in all trimesters

›Avoid doxycycline in pregnancy

›Risk of fetal dental staining and bone growth inhibition

›Avoid TMP-SMX in first trimester and near term

›Neural tube defect risk in first trimester

›Neonatal hyperbilirubinemia risk near term

›Vancomycin IV: use with monitoring if MRSA and systemic infection

›Renal monitoring more frequent in pregnancy

›Drainage in pregnancy

›Ultrasound-guided aspiration preferred for anaesthetic safety

›Avoid prone positioning for procedures in late pregnancy

›Regional anaesthetic technique preferred

›Consult obstetrics for any procedure requiring sedation

Geriatric

›Geriatric-specific considerations

›Breast abscess less common in post-menopausal women

›Non-lactational abscess in older adults: higher index of suspicion for malignancy

›IBC and carcinoma must be excluded before attributing to infection alone

›Atypical presentation

›Blunted fever response: infection may be present without fever

›Delirium as presenting feature of systemic infection

›Leukocytosis may be absent in immunosenescent state

›Antibiotic dosing adjustments

›Renal function assessment mandatory before antibiotic dosing

›Creatinine clearance (CrCl) calculation: Cockcroft-Gault equation

›Vancomycin: renal dose adjustment; CrCl-guided interval

›TMP-SMX: reduce dose if CrCl <30 ml/min

›Drug interaction assessment

›Polypharmacy common in geriatric patients

›Warfarin and TMP-SMX: INR elevation (CYP2C9 inhibition)

›Warfarin and metronidazole: INR elevation

›Malignancy vigilance

›Any geriatric breast abscess that fails to resolve within 7–10 days of antibiotics

›Biopsy required to exclude IBC or underlying carcinoma

›Urgent referral to breast surgery or oncology

Pediatrics

›Pediatric breast abscess considerations

›Neonatal mastitis and abscess

›Neonatal breast bud inflammation: physiologic in first weeks of life

›Neonatal mastitis: usually S. aureus; erythema, warmth, induration

›Neonatal abscess: requires drainage and IV antibiotics

›Adolescent breast abscess

›Periareolar abscesses common in adolescent females

›Associated with physiologic breast development

›Often recurrent; smoking cessation relevant in adolescents who smoke

›Antibiotic dosing in pediatrics

›Cephalexin 25–50 mg/kg/day orally divided four times daily

›Maximum 4 g/day

›Safe in all ages including neonates

›Clindamycin 10–20 mg/kg/day orally divided three or four times daily

›MRSA oral outpatient coverage in children

›Maximum 1.8 g/day

›Vancomycin IV 40–60 mg/kg/day divided every 6 hours

›Neonates: 10–15 mg/kg IV every 12 hours (renal adjustment)

›AUC-guided monitoring preferred

›Neonatal specific management

›Neonatal abscess: hospitalize for IV antibiotics and surgical drainage

›Antistaphylococcal IV coverage: nafcillin 50–75 mg/kg/day divided every 6 hours

›MRSA concern: vancomycin IV 10–15 mg/kg every 12 hours in neonates

›Drainage technique in neonates

›Stab incision preferred over aspiration in neonates due to viscous pus

›Minimize incision size to preserve breast bud

10Background/b67

Epidemiology

›Incidence and prevalence

›Approximately 3% of women with mastitis develop a breast abscess

›Lactational mastitis affects up to 10% of breastfeeding women

›Lactational abscess most common form

›Age distribution

›Lactational abscess: predominantly women aged 18–50

›Peak incidence first 2–3 months postpartum

›Age >30 and primiparity are independent risk factors

›Non-lactational abscess demographics

›Periductal mastitis (PDM-SMOLD): predominantly premenopausal women who smoke

›Recurrent subareolar abscess: strong smoking association

›Microbiology

›S. aureus is the most common causative organism

›MRSA accounts for 25–50% of S. aureus breast abscesses in some series

›MRSA role increasing in community-acquired breast infections

›Non-lactational polymicrobial infections

›Anaerobes: Bacteroides, Peptostreptococcus

›Streptococcal species

›Enterococcal species in diabetic or immunocompromised hosts

›Risk factors and natural history

›Delayed treatment of mastitis (onset ≥2 days before presentation) increases abscess risk

›Non-professional breast massage is an independent risk factor for abscess progression

›Recurrence rate is low when guidelines followed for lactational abscess

›Non-lactational and PDM-SMOLD have higher recurrence rates requiring surgical referral

Pathophysiology

›Lactational abscess formation

›Sequence: nipple trauma → ductal bacterial entry → mastitis → abscess

›S. aureus enters via cracked nipple or excoriation

›Milk stasis from missed feedings or poor drainage promotes bacterial growth

›Unresolved mastitis progresses to localized abscess over 24–72 hours

›Histology

›Central liquefactive necrosis with polymorphonuclear infiltrate

›Peripheral fibrous capsule formation over time

›Non-lactational abscess (periductal mastitis / PDM-SMOLD)

›Squamous metaplasia of lactiferous duct epithelium

›Keratin plug formation obstructs duct lumen

›Secondary bacterial infection with mixed flora (anaerobes and aerobes)

›Subareolar abscess forms; fistula to skin common with recurrence

›Smoking as mechanistic driver

›Nicotine and toxic metabolites cause squamous metaplasia

›Impaired neutrophil function and local immunity

›IBC pathophysiology (key differential)

›Lymphatic obstruction by tumor emboli in dermal lymphatics

›Results in peau d'orange and skin erythema

›No true infection: antibiotics ineffective as definitive treatment

›HER2 overexpression common in IBC

Therapeutic Considerations

›Drainage approach rationale

›Needle aspiration vs incision and drainage

›Aspiration yields equivalent cure rates with better cosmesis

›Cochrane 2015 review: aspiration and I&D comparable outcomes in lactational abscess

›ASBrS 2025: aspiration preferred for <3 cm collections

›No wound packing principle

›Wound packing is no longer recommended

›Gravity drain placement reduces healing time and discomfort

›Drain removed in 3–5 days after placement

›Antibiotic stewardship

›Culture-directed therapy reduces unnecessary broad-spectrum antibiotic use

›All drained collections should have fluid sent for culture

›De-escalate from MRSA coverage if culture shows MSSA

›Duration principles

›Minimum 10 days for abscess with phlegmon

›10–14 days standard for drained abscess

›Extend if clinical improvement incomplete at day 10

›Breastfeeding continuation

›Breastfeeding continuation is safe and beneficial

›Reduces milk stasis and promotes drainage

›Infant not harmed by continuing breastfeeding during maternal abscess or antibiotic therapy

›ASBrS 2025: breastfeeding should be encouraged and supported

11Patient Discharge Instructions/pdi37

copy discharge instructions

›Breast Abscess — Discharge Instructions

›Your diagnosis

›You have been treated for a breast abscess, which is a collection of infected fluid in the breast

›Your infection was drained today and you have been given antibiotics to clear the remaining infection

›Wound care

›Keep the drainage site clean and dry

›Change dressings as instructed by your care team, usually once daily

›If a drain was placed, do not remove it yourself — it will be removed at your follow-up appointment in 3–5 days

›Do not pack the wound yourself

›Antibiotics

›Take all antibiotics as prescribed, even if you feel better

›Do not stop early without speaking to your doctor

›Take with food to reduce stomach upset

›Breastfeeding

›It is safe to continue breastfeeding from both breasts

›Breastfeeding helps prevent milk buildup and promotes healing

›Do not aggressively massage your breast or over-pump; this can worsen the infection

›Contact a lactation consultant if you are having difficulty with latch or feeding

›Pain management

›Take ibuprofen (Advil, Motrin) 400–600 mg every 6–8 hours with food as needed for pain

›Acetaminophen (Tylenol) 650 mg every 6 hours can be added for additional relief

›Both are safe while breastfeeding at recommended doses

›Follow-up

›Return to your doctor or the clinic in 48–72 hours for a wound check

›If a drain was placed, your drain removal appointment is in 3–5 days

›If you are a non-breastfeeding woman, you should have a repeat breast imaging when the infection has fully resolved

›Return to emergency department immediately if

12References/r33

Guidelines and key sources

›ASBrS 2025 Guidelines (Mitchell KB et al., JAMA Surgery 2026)

›American Society of Breast Surgeons, Society of Breast Imaging, and College of American Pathology 2025 Guidelines for the Management of Infectious and Inflammatory Lesions of the Breast

›Recommends aspiration for <3 cm abscesses; stab incision with gravity drain for 3–5 cm lactational abscesses

›Recommends against wound packing; advises breastfeeding continuation; discourages aggressive breast massage

›Cochrane Systematic Review (Irusen H et al., 2015)

›Treatments for Breast Abscesses in Breastfeeding Women — Cochrane Database of Systematic Reviews

›Aspiration yields equivalent cure rates to I&D with superior cosmesis

›S. aureus most common organism; MRSA increasingly prevalent

›IDSA Skin and Soft Tissue Infections Guidelines (Stevens DL et al., Clinical Infectious Diseases 2014)

›Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update

›Non-lactational abscess: amoxicillin-clavulanate first-line for anaerobic coverage

›MRSA: TMP-SMX or doxycycline outpatient; vancomycin inpatient

Supporting evidence

›Li D et al., PloS One 2022

›Risk factors and prognosis of acute lactation mastitis developing into breast abscess: retrospective longitudinal study

›Age >30, primiparity, gestational age ≥41 weeks, and non-professional breast massage identified as independent risk factors

›Morcomb EF et al., American Family Physician 2024

›Mastitis: Rapid Evidence Review

›Non-lactating patients with breast erythema have higher suspicion for malignancy

›Hester RH et al., American Journal of Obstetrics and Gynecology 2021

›Inflammatory Breast Cancer: Early Recognition and Diagnosis Is Critical

›Erythema involving ≥1/3 of breast, peau d'orange, and absence of infectious trigger: IBC until proven otherwise

›Rashid T et al., British Journal of Radiology 2023

›Breast Imaging of Infectious Disease

›Ultrasound: first-line imaging for breast abscess; guides drainage; distinguishes abscess from phlegmon

›ACEP Ultrasound Guidelines 2023

›Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine

Learn More: Breast Abscess→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.